Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
批准号:
8838727
负责人:
Yong Wan
金额:
$30.82万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-05 至 2017-04-30
关键词:
AddressAntineoplastic AgentsAttenuatedBindingBiologicalBiological AssayCDC2 Protein KinaseCancerousCell-Free SystemCellsChimeric ProteinsComplexCutaneous MelanomaDNA DamageDNA RepairDNA damage checkpointDataDevelopmentDown-RegulationDropsDysplasiaExcisionExposure toFailureFunctional disorderFutureGenesGenome StabilityGenotoxic StressHepatocyte Growth FactorHumanKnowledgeLeadMalignant - descriptorMalignant NeoplasmsMediatingMediationMicroscopyModelingMolecularMusPathogenesisPathway interactionsPhosphorylationPlayProcessProtein BindingProteinsProteolysisRad17 proteinRegulationRegulation of ProteolysisResearchRoleSignal TransductionSkinSpecimenStagingSystemTestingTherapeuticTherapeutic InterventionTimeUV Radiation ExposureUV inducedUV-induced melanomaUbiquitinUbiquitin-Protein Ligase ComplexesUltraviolet Raysbasecarcinogenesischromatin immunoprecipitationdesigngenome integritymelanocytemelanomamouse modelmulticatalytic endopeptidase complexmutantnovelprotein degradationreconstructionresponsetumorigenesisubiquitin-protein ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Failure of DNA damage checkpoint regulation can predispose a cell to become cancerous. The ubiquitin-proteosome system (UPS) is thought to play an important role in regulating responses to DNA damage and DNA repair. In attempting to further define this role, we have observed that a critical component of the regulatory machinery, Rad17, is a UV-induced and ubiquitin-dependent fast-turnover protein. We observed that temporal degradation of Rad17 by Cdh1/APC (ubiquitin-protein ligase) is involved in terminating checkpoint signaling after the completion of the checkpoint response, and that stabilization of Rad17 through functional interference by a non-degradable Rad17 mutant attenuates checkpoint termination and the removal of DNA-damaged cells. We have further observed that impaired proteolysis and persistently elevated Rad17 is a conspicuous feature of malignant melanomas, and that the level of persistence parallels the transition from normal melanocyte through an increasing degree of dysplasia and ultimately to melanoma itself. In addition, stabilized Rad17 impedes genomic integrity, which induces malignant transformation for human primary melanocytes. Our objective in the proposed study is to elucidate details underlying Rad17-mediated checkpoint dysregulation, and examine its impact to the process of melanomagenesis. We seek to assess the extent to which Rad17 persistence may play a pathogenetic role in some cancers. Based on the evidence, we hypothesize that failure of checkpoint regulation is an important facilitator of the development of melanomas and possibly other cancers as well. Our Specific Aims are the following: (1) To determine the upstream mechanism that regulates Cdh1 and further examine how the interplay between Cdh1/APC and Rad17 terminates checkpoint signaling; (2) to study how Rad17 is regulated by Cdh1/APC during the DNA damage response; and (3) to determine the impact of dysregulated Rad17 proteolysis on carcinogenesis using an established melanoma mouse model and 3D skin reconstruction model. Understanding the biological mechanisms involved in genomic integrity via Rad17 proteolytic regulation and elucidating a potential role for Rad17 proteolysis in melanoma development will be an important antecedent to future studies on the role of impaired DNA damage signaling in oncogenesis, as well as for efforts to identify potential targets for therapeutic intervention.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1186/s13008-016-0021-6
发表时间:
2016
期刊:
Cell division
影响因子:
2.3
作者:
[Zhou Z, He M, Shah AA, Wan Y]
通讯作者:
Wan Y
DOI:
10.1186/s13008-016-0013-6
发表时间:
2016
期刊:
Cell division
影响因子:
2.3
作者:
[He M, Zhou Z, Shah AA, Hong Y, Chen Q, Wan Y]
通讯作者:
Wan Y
Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication.
配音在肿瘤转移和凋亡中的新兴作用:治疗意义。
DOI:
10.1016/j.pharmthera.2017.03.001
发表时间:
2017-09
期刊:
Pharmacology & therapeutics
影响因子:
13.5
作者:
[He M, Zhou Z, Wu G, Chen Q, Wan Y]
通讯作者:
Wan Y
DOI:
10.1186/s13578-016-0127-1
发表时间:
2016
期刊:
Cell & bioscience
影响因子:
7.5
作者:
[He M, Zhou Z, Shah AA, Zou H, Tao J, Chen Q, Wan Y]
通讯作者:
Wan Y
DOI:
10.1016/j.ebiom.2016.12.014
发表时间:
2017-02
期刊:
EBioMedicine
影响因子:
11.1
作者:
[Zhou Z, Luo A, Shrivastava I, He M, Huang Y, Bahar I, Liu Z, Wan Y]
通讯作者:
Wan Y
共 6 条
Targeting posttranslational modifications of CD73 in TNBCs
-
批准号:10359179
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy
-
批准号:10361572
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting Posttranslational Modifications in Breast Carcinogenesis
-
批准号:10365966
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy
-
批准号:10523400
-
项目类别:
-
资助金额:$51.82万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting Posttranslational Modifications in Breast Carcinogenesis
-
批准号:10523396
-
项目类别:
-
资助金额:$46.22万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting posttranslational modifications of CD73 in TNBCs
-
批准号:10184613
-
项目类别:
-
资助金额:$65.92万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy
-
批准号:10181635
-
项目类别:
-
资助金额:$52.25万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Interplay between ER and TGF-b in carcinogenesis
-
批准号:10523253
-
项目类别:
-
资助金额:$17.3万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Targeting posttranslational modifications of CD73 in TNBCs
-
批准号:10523388
-
项目类别:
-
资助金额:$66.4万
-
财政年份:2021
-
负责人:Yong Wan
-
依托单位:
Interplay between ER and TGF-b in carcinogenesis
-
批准号:9655714
-
项目类别:
-
资助金额:$26.11万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Interplay between ER and TGF-b in carcinogenesis
-
批准号:9512889
-
项目类别:
-
资助金额:$12.2万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Targeting interplay between KLF4 and PRMT5 in carcinogenesis
-
批准号:9977693
-
项目类别:
-
资助金额:$25.32万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Interplay between ER and TGF-b in carcinogenesis
-
批准号:9181828
-
项目类别:
-
资助金额:$38.2万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Interplay between ER and TGF-b in carcinogenesis
-
批准号:10084161
-
项目类别:
-
资助金额:$8.12万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Targeting interplay between KLF4 and PRMT5 in carcinogenesis
-
批准号:9181842
-
项目类别:
-
资助金额:$38.06万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Targeting interplay between KLF4 and PRMT5 in carcinogenesis
-
批准号:9564343
-
项目类别:
-
资助金额:$25.99万
-
财政年份:2016
-
负责人:Yong Wan
-
依托单位:
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
-
批准号:8657891
-
项目类别:
-
资助金额:$29.92万
-
财政年份:2011
-
负责人:Yong Wan
-
依托单位:
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
-
批准号:8458491
-
项目类别:
-
资助金额:$29.01万
-
财政年份:2011
-
负责人:Yong Wan
-
依托单位:
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
-
批准号:8184804
-
项目类别:
-
资助金额:$30.46万
-
财政年份:2011
-
负责人:Yong Wan
-
依托单位:
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis
-
批准号:8296553
-
项目类别:
-
资助金额:$30.19万
-
财政年份:2011
-
负责人:Yong Wan
-
依托单位:
海外基金